- Home
- ASIC vs AVTX Comparison
ASIC vs AVTX Comparison
Compare ASIC & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ASIC | AVTX |
|---|---|---|
| Founded | 2018 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 982.5M |
| IPO Year | 2025 | 2015 |
Fundamental Metrics
Financial Performance| Metric | ASIC | AVTX |
|---|---|---|
| Price | $27.53 | $16.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $26.75 | ★ $40.57 |
| AVG Volume (30 Days) | 53.4K | ★ 685.2K |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 23.44 | ★ 72.07 |
| EPS | ★ 1.18 | N/A |
| Revenue | ★ $424,339,000.00 | $27,813,137.00 |
| Revenue This Year | $34.21 | N/A |
| Revenue Next Year | $34.65 | N/A |
| P/E Ratio | $22.99 | ★ N/A |
| Revenue Growth | 23.41 | ★ 2312.27 |
| 52 Week Low | $16.35 | $9.54 |
| 52 Week High | $27.90 | $24.27 |
Technical Indicators
Market Signals| Indicator | ASIC | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 60.01 | 38.74 |
| Support Level | $18.56 | $17.40 |
| Resistance Level | $27.22 | $18.78 |
| Average True Range (ATR) | 0.99 | 0.92 |
| MACD | 0.01 | -0.25 |
| Stochastic Oscillator | 69.01 | 3.06 |
Price Performance
Historical ComparisonAbout ASIC Ategrity Specialty Insurance Company Holdings
Ategrity Specialty Insurance Co Holdings is a specialty property and casualty insurance holding company focused on the excess and surplus market for small to medium-sized businesses (SMBs) across the United States. Operating through its subsidiaries, the company underwrites small and medium-sized commercial risks across selected industry verticals, including Retail, Real Estate, Hospitality, and Construction. Its operating model uses a technology-driven method to standardize, simplify, and, where appropriate, automate these transactions. The group distributes its products through licensed surplus lines brokers and wholesale agents.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.